Noraver NTF Jarabe

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Noraver NTF Jarabe

Property Description
Active ingredient Bromhexine
Form Jarabe (Syrup) / Oral Liquid
Pharmacological class Mucolytic and Secretolytic
Common use Easing respiratory congestion
Origin Synthetic organic compound

What Type of Medicine is Noraver NTF Jarabe?

Noraver NTF Jarabe is an oral liquid medicine, presented as a Jarabe or syrup, whose primary function is to modify the physical properties of respiratory mucus. It is classified as a mucolytic and secretolytic agent, placing it in the broader category of respiratory medications that specifically target secretions rather than suppressing the cough itself.

The product contains the single active component, Bromhexine, which is a synthetic organic compound structurally related to the plant alkaloid vasicine. Its syrup form ensures a measured and convenient oral administration route, allowing for systemic delivery of the active substance intended to address chest congestion originating from the lower airways.


Bromhexine: Composition and High-Level Action

The active pharmaceutical ingredient is Bromhexine, typically formulated as its hydrochloride salt, which serves as a modifier of thickened, adherent mucus. Bromhexine works primarily by reducing the high viscosity of retained phlegm, thereby facilitating its mobilization and clearance. This mechanism is associated with managing mucus-associated respiratory difficulties.

This action involves breaking down the long, complex mucopolysaccharide fibers within the mucus structure, an effect that liquefies the secretions. Concurrently, the drug stimulates the glands lining the bronchial passages to increase the production of less viscous, serous fluid. These secretolytic agents aid in enhancing the clearance mechanism of the respiratory tract, ultimately improving the flow of air and secretions.


How Does Noraver NTF Jarabe Generally Help?

Noraver NTF Jarabe generally helps by transforming dense, tenacious respiratory secretions into a more fluid state, which alleviates the discomfort associated with a congested chest. The secretolytic nature of the drug ensures that the effort involved in producing a productive cough is effective, rather than being hindered by overly sticky phlegm. The general benefit is focused on reducing the physical effort required to clear the airways and promoting the natural, necessary expulsion of secretions from the bronchial passages.

Advertisements

What side effects are possible with Noraver NTF Jarabe?

Possible side effects and safety information

Noraver NTF Jarabe, containing the active substance Bromhexine, has an officially documented safety profile characterized by categorized adverse reactions and specific usage limitations. The information is structured according to regulatory standards (e.g., EMA/ICH frequency bands).

Adverse reactions are grouped by the body system affected, known as System-Organ Classes (SOCs). The most commonly observed reactions (classified as Rare or Very Rare in regulatory documents) affect the Gastro-intestinal system, presenting as nausea, vomiting, diarrhoea, or upper abdominal pain. Other effects include headache, dizziness, sweating, and Skin and subcutaneous tissue disorders like rash and urticaria.

Serious Adverse Reactions

The regulatory profile highlights rare but clinically significant risks, primarily affecting the Immune system and Skin. These Serious Adverse Reactions include Anaphylactic reaction (up to anaphylactic shock), Angioedema, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). SCARs are often classified as frequency Not Known and may be preceded by flu-like symptoms.

Safety Restrictions and Special Populations

Use of the medicine is contraindicated in patients with a known hypersensitivity to bromhexine. Caution is necessary for individuals with a history of gastric or duodenal ulceration and those with severe hepatic or renal impairment, as reduced clearance of the medicine or its metabolites may occur. The official label advises against using this medicine concurrently with antitussive (cough suppressant) agents, as this can lead to the dangerous accumulation of mobilized bronchial secretions. Safety notes also advise caution for use during pregnancy and lactation, and restriction for children under two years of age.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents state that no specific overdose symptoms have been reported in humans for the active ingredient, Bromhexine. Observed manifestations in cases of overexposure or accidental overdose are generally consistent with the drug’s known adverse effects.

Documented Manifestations and Serious Outcomes

Classification Manifestation/System Affected
Common Signs Nausea, vomiting, headache, dizziness, diarrhoea, upper abdominal pain.
Serious Outcomes Anaphylactic reactions (including shock) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS).

Required Emergency Actions

In the event of an overdose or suspected overexposure, the official regulatory mandate is to immediately contact the Poisons Information Centre or equivalent emergency services. No specific antidote is known, and management is restricted to symptomatic and supportive treatment for any manifesting signs.

Urgent medical attention is required if signs of severe allergic reaction occur, including difficulty breathing or swelling of the face, lips, tongue, or throat. Immediate medical advice must also be sought if a progressive skin rash associated with blisters or mucosal lesions develops, which may indicate a SCAR.

Advertisements

Therapeutic Uses of Noraver NTF Jarabe

Quick Facts

  • Primary Use: Symptomatic management of a dry, non-productive cough.
  • Target Conditions: May help relieve persistent coughing related to various respiratory irritations.
  • Patient Benefit: Supports reduced frequency and severity of the cough reflex.

Therapeutic Overview

Noraver NTF Jarabe is used in the management of coughs that are characterized as dry and non-productive (coughs that do not produce mucus). This therapeutic choice is designed for the symptomatic relief of irritating coughs arising from various respiratory sources, such as those that may accompany viral infections or bronchial inflammation.

The medication may support the reduction of the urge to cough, which may help patients achieve periods of rest and comfort. Its primary function is focused on providing symptomatic control of the cough reflex to alleviate associated distress. Relief may be experienced by patients dealing with the persistent irritation of a dry cough.

Butamirate citrate, the active agent, is used for its utility in suppressing cough reflexes.

This medication is a therapeutic choice for individuals seeking to manage the discomfort and frequency of an irritating, dry cough.

Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

Noraver NTF Jarabe (containing Tenofovir Disoproxil Fumarate - TDF) has specific eligibility rules mandated by government regulatory bodies.

Classification Status & Population
Contraindication Prohibited for individuals with known hypersensitivity to TDF or any components.
Pediatric Use Allowed for children mathbf2 years of age and older weighing at least mathbf10 kg. Safety and efficacy are not established for infants under 2 years.
Renal Function Restricted use in patients with compromised kidney function. Use is not recommended in patients with mathbf severe renal impairment (Creatinine Clearance <30 mL/min) or those requiring hemodialysis.
Pregnancy Use is permitted only if the potential benefit justifies the potential risk, as determined by a healthcare professional.
Lactation Not recommended for nursing mothers as the drug is passed into breast milk, which may pose a risk to the infant.

Special Consideration: Use is generally permitted for adults, but the label advises caution in older adults due to the greater frequency of age-related decreases in organ function.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Noraver NTF Jarabe contains the active substance Bromhexine, a mucolytic agent whose official interaction profile is defined by pharmacodynamic conflict and pharmacokinetic considerations, as documented by regulatory authorities. The profile does not list any mandatory contraindicated drug combinations.


Documented Interaction Patterns

Interaction Type Interacting Substance/Condition Official Regulatory Description
Pharmacodynamic Conflict Antitussive Agents (Cough Suppressants) Concomitant use is associated with the risk of accumulation of bronchial secretions due to the suppression of the natural cough reflex.
Drug Distribution Alteration Certain Antibiotics (e.g., Amoxicillin, Erythromycin, Oxytetracycline) Co-administration leads to an increase in the concentration of these antibiotics within the bronchopulmonary secretions.
Pharmacokinetic Influence Food Intake Intake with food is officially documented to increase the systemic bioavailability (plasma concentration) of Bromhexine.

Population and Clearance Considerations

Clearance of Bromhexine or its metabolites may be reduced in individuals with severe hepatic impairment (severe liver disease) or severe renal impairment (severe kidney failure). This is a pharmacokinetic consideration noted in official prescribing information. Regulatory data indicates that interactions involving major metabolic enzymes, such as CYP2C9 or CYP3A4 substrates, are considered unlikely.

Advertisements

Mechanism of Action

The mechanism of Noraver NTF Jarabe, containing Bromhexine, is defined by a dual action that modulates the fluid dynamics and structure of secretions in the respiratory tract. The mucolytic mechanism involves promoting the release of lysosomal enzymes from secretory cells, which facilitates the hydrolytic depolymerization of acid mucopolysaccharide fibres. These complex mucin chains are responsible for the high viscoelasticity and adhesiveness of bronchial secretions. Concurrently, the secretolytic mechanism involves the stimulation of submucosal glands. This interaction shifts the balance of glandular output, resulting in an increased volume and proportion of thin, serous fluid within the airways. This increase in hydration and the structural breakdown of mucins reduce the physical resistance of the mucus layer. The resulting physiological consequence is the functional optimization of the ciliated epithelium, which allows for the propulsion of the now-fluidized secretions.

Advertisements

Dosage and Administration Information

How to Use Noraver NTF Jarabe: Administration Guidelines

Noraver NTF Jarabe is an oral liquid formulation containing the active substance Bromhexine, and its usage is defined by specific administration patterns.


Administration Scope

The medicine is intended for oral administration as a short-term course of therapy.

Usage Parameter Instruction
Route of Administration Oral
Dosing Frequency Three times daily (t.i.d.) or Every 8 hours
Preparation The container must be shaken well prior to administration
Timing Relative to Meals Some labeling specifies administration immediately after meals
Course Duration Restricted to a short-term course, typically not exceeding 7 to 10 days

Labeled Dosing Regimens

Standard dosing is structured by age group, with doses measured using the specific device supplied with the syrup.

Population Standard Single Dose
Adults and Children 12+ years 10 mL (8 mg). May be increased to 20 mL (16 mg) per dose.
Children 6 to 11 years 5 mL (4 mg) or 10 mL (8 mg)
Children 2 to 5 years 2.5 mL (2 mg)

Procedural Conditions

Standard instructions note that dose modification or close monitoring may be required for patients experiencing severe hepatic or renal impairment due to the potential for reduced drug clearance. Standard procedural practice indicates that a missed dose should be skipped if the next dose is due soon, and a double dose must not be taken to compensate for the missed administration.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Research has examined this combination drug in adults with Type 2 diabetes. Findings from clinical trials and meta-analyses were reviewed to summarize the observed data points and patient tolerability.


Efficacy Data: Blood Glucose Management

Research evaluated whether the combination drug was studied in relation to changes in blood glucose levels in patients with Type 2 diabetes.

  • Glycemic Control: Studies have reported findings regarding fasting plasma glucose (FPG) and glycosylated hemoglobin ( HbA1c) associated with this combination therapy. One large meta-analysis summarized findings regarding its findings for long-term use.
  • Cardiovascular and Macrovascular Outcomes: Other studies explored whether research findings included assessment of macrovascular complications. The primary focus focused on the reporting of major adverse cardiovascular events (MACE). Evidence remains limited regarding long-term cardiovascular impact.

Pharmacokinetic and Adverse Event Profile

The tolerability and adverse event profile was documented across all phases of clinical research, including common side effects and drug interactions.

  • Administration: Studies examined the administration of this drug with food in relation to absorption. Data was collected on plasma concentration when administered at different times relative to meals.
  • Renal and Hepatic Function: Research has addressed kidney function monitoring during the initiation of treatment. Data was also collected regarding hepatic function in patients with pre-existing mild to moderate impairment.

Comparative Studies

Studies are currently exploring whether this combination therapy demonstrates different outcomes compared to monotherapy alone. Results have been reported regarding the comparison of this combination therapy against an active comparator of a different drug class.

Key Studies & References ADA and KDIGO Consensus Report for Diabetes Management in Chronic Kidney Disease (Guidelines)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Noraver NTF Jarabe (FAQ)


Q: What is Noraver NTF Jarabe used for?

According to the official product information, Noraver NTF Jarabe is indicated for the temporary relief of symptoms associated with various causes, such as common colds, allergies, and influenza. Specifically, it is used to help manage nasal congestion and discharge, sneezing, itchy and watery eyes, and cough.

Q: Is Noraver NTF Jarabe recommended for relieving a sore throat?

The regulatory documents for Noraver NTF Jarabe indicate that it is used for the temporary relief of cough, which is often a component of an irritated throat. However, the product information primarily focuses on the relief of respiratory and allergic symptoms like congestion, runny nose, and sneezing, rather than directly listing sore throat as a sole primary indication.

Q: How long does Noraver NTF Jarabe take to start working?

Official information indicates that the active ingredients may start to provide relief relatively quickly, typically within an hour of administration. However, the exact timing of the onset of effect can vary for each individual. The duration of the effect is generally considered to be up to several hours.

Q: What should I do if I miss a dose of Noraver NTF Jarabe?

Regulatory documents describe a protocol for handling a missed dose: if a dose is missed, it is generally recommended to take it promptly unless the time for the next dose is near. The instructions emphasize that doubling the dose to compensate is not advised. Detailed instructions can be found in the dedicated 'How to use' section.

Q: Can Noraver NTF Jarabe be used for cough caused by asthma?

The product information states that it is not intended for chronic coughs, such as those related to asthma. It is indicated for temporary cough relief associated with common colds, flu, and allergies. The use of this product by individuals with pre-existing respiratory issues is not supported by the primary indications.

Q: Does Noraver NTF Jarabe contain an antihistamine?

Yes, regulatory documents confirm that Noraver NTF Jarabe contains the ingredient chlorphenamine, which is a type of antihistamine. This component helps to relieve allergic symptoms like sneezing, watery eyes, and runny nose. The other main active ingredients contribute to cough suppression and nasal decongestion.

Q: Does this medicine cause drowsiness or affect my ability to drive?

Official product information states that one of the active ingredients, chlorphenamine, may cause drowsiness in some individuals. Due to the potential for drowsiness, the product information advises that individuals should be aware of how the medicine affects them before engaging in activities that require full mental alertness, such as driving or operating heavy equipment.

Advertisements

How should Noraver NTF Jarabe be stored and disposed of?

How to Store and Dispose of Noraver NTF Jarabe

Noraver NTF Jarabe, which contains Bromhexine oral liquid, must be stored under specific environmental conditions to maintain its stability.

Storage Requirements

Condition Requirement
Temperature Do not store the medicine above 30 C (86 F).
Protection Keep the bottle inside the outer carton to protect the product from light.
Child Safety The product must be kept out of the sight and reach of children.

Disposal

Any unused or expired Noraver NTF Jarabe, or the waste material from its use, must be disposed of in accordance with local requirements. Official guidelines state that disposal should adhere to established procedures for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noraver NTF Jarabe found in:

A-Z Index: